4564.T Stock Falls 4% on April 27 as OncoTherapy Science Faces Headwinds

OncoTherapy Science, Inc. (4564.T) traded lower on April 27, 2026, with 4564.T stock declining 4% to close at ¥24.0 on the JPX. The Kawasaki-based biotech firm saw volume surge to 157.4 million shares, more than double its average. This weakness reflects broader market concerns about the company’s clinical pipeline and financial performance. OncoTherapy develops cancer therapies and peptide vaccines, but negative fundamentals have weighed on investor sentiment. The stock now trades well below its ¥35.0 year high, signaling sustained pressure in the biotech sector.

4564.T Stock Price Action and Market Sentiment

OncoTherapy Science’s 4564.T stock opened at ¥23.0 and traded between ¥22.0 and ¥25.0 before closing at ¥24.0, down ¥1.0 from the previous close of ¥25.0. The 4% decline marks the fifth consecutive day of weakness, with the stock down 14.3% over five days. Volume exploded to 157.4 million shares, representing 2.29x average daily volume, suggesting institutional selling pressure.

The broader healthcare sector on JPX declined 0.67% on the day, but OncoTherapy underperformed peers. The stock trades at a price-to-book ratio of 4.05x, well above the healthcare sector average of 2.16x. This valuation premium appears unjustified given the company’s negative earnings. Track 4564.T on Meyka for real-time updates on this volatile biotech name.

Financial Metrics and Valuation Concerns

OncoTherapy Science reports deeply negative fundamentals that explain the market’s skepticism. The company posted a negative EPS of -¥2.83 and a negative PE ratio of -8.48, indicating ongoing losses. Revenue per share stands at just ¥2.17, while the company burns cash with negative net income per share of -¥2.44.

The price-to-sales ratio of 10.52x ranks among the highest in the biotech space, suggesting investors are pricing in significant future growth that may not materialize. Return on equity sits at a dismal -63%, while return on assets is -35.5%. The company maintains a strong cash position of ¥6.06 per share, but at current burn rates, runway remains limited. Meyka AI rates 4564.T with a grade of B, suggesting a HOLD recommendation. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

Clinical Pipeline and Product Development

OncoTherapy’s pipeline includes multiple candidates across different development stages. OTS167, a maternal embryonic leucine zipper kinase inhibitor, is in Phase I/II trials for acute myeloid leukemia and Phase I trials for breast cancer. OTS964, a T-LAK cell-originated protein kinase inhibitor, targets various cancer diseases but remains early-stage.

The company’s cancer-specific peptide vaccines show more promise. S-588410 advanced to Phase III trials for esophageal cancer and Phase II for bladder cancer. S-488210 is in Phase I/II for head and neck cancer, while S-588210 targets solid tumors in Phase I. Additionally, OTSA101 and KHK6640 represent antibody drug candidates for synovial sarcoma and Alzheimer’s disease respectively. With 540 full-time employees and headquarters in Kawasaki, the company maintains focused R&D efforts, though clinical success remains uncertain.

Market Sentiment and Technical Outlook

Technical indicators reveal mixed signals for 4564.T stock. The RSI of 48.01 suggests neutral momentum, while the MACD histogram of -0.23 indicates weakening momentum. The ADX of 44.18 signals a strong downtrend, confirming the recent selling pressure. Bollinger Bands show the stock trading near the middle band at ¥25.10, with support at ¥20.04 and resistance at ¥30.16.

Meyka AI’s forecast model projects ¥17.31 for the next 12 months, implying 28% downside from current levels. The three-year forecast of ¥12.52 suggests continued pressure. Forecasts are model-based projections and not guarantees. Analyst consensus remains absent, leaving investors to rely on fundamental analysis. The company reports earnings on May 11, 2026, which could provide clarity on cash burn and pipeline progress. Until then, volatility should persist.

Final Thoughts

OncoTherapy Science’s 4564.T stock declined 4% to ¥24.0 on April 27, 2026, driven by negative earnings, high cash burn, and an unproven pipeline. Despite a strong cash position, the path to profitability remains unclear and valuation appears stretched. Technical indicators confirm downtrend momentum. Investors should wait for May 11 earnings results before reassessing positions. This speculative biotech stock offers limited near-term catalysts, making it suitable only for risk-tolerant investors willing to monitor clinical trials and cash runway closely.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.